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Background
The World Health Organization classification of myeloproliferative neoplasms discriminates
between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis. This
discrimination is clinically relevant because essential thrombocythemia is associated with a
favorable prognosis whereas patients with primary myelofibrosis have a higher risk of  progres-
sion to myelofibrosis or blast crisis. 
Design and Methods
To assess the reproducibility of the classification, six hematopathologists from five European
countries re-classified 102 non-fibrotic bone marrow trephines, obtained because of sustained
thrombocytosis.  
Results
Consensus on histological classification defined as at least four identical diagnoses occurred for
63% of the samples. Inter-observer agreement showed low to moderate kappa values (0.28 to
0.57, average 0.41). The percentage of unclassifiable myeloproliferative neoplasms rose from
2% to 23% when minor criteria for primary myelofibrosis were taken into account. In contrast,
the frequency of primary myelofibrosis dropped from 23% to 7%, indicating that the majority
of patients with a histological diagnosis of primary myelofibrosis did not fulfill the complete
criteria for this disease. Thus, over 50% of cases in this series either could not be reproducibly
classified or fell into the category of unclassifiable myeloproliferative neoplasms. 
Conclusions
World Health Organization criteria for discrimination of essential thrombocythemia from pre-
fibrotic primary myelofibrosis are poorly to only moderately reproducible and lead to a higher
proportion of non-classifiable myeloproliferative neoplasms than histology alone. 
Key words: myeloproliferative diseases, essential thrombocythemia, primary myelofibrosis.
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Introduction
The classification of BCR-ABL-negative myeloprolifera-
tive neoplasms (MPN) has been a matter of debate for
decades. The recent World Health Organization (WHO)
classification discriminates between essential thrombo-
cythemia (ET), primary myelofibrosis (PMF) and poly-
cythemia vera (PV).1,2 It is the differentiation between the
first two entities, both presenting with non-reactive
thrombocytosis, which causes particular controversy.3-6
Fibrosis in PMF may follow a non-fibrotic cellular phase in
a proportion of cases. This proliferation is clonal in nature7
and has previously been designated chronic megakary-
ocytic-granulocytic myelosis,8 cellular idiopathic myelofi-
brosis9 or cellular primary myelofibrosis.1,2 Three major
and four minor criteria have been included in the WHO
scheme to define PMF and to discriminate it from ET and
other MPN. All three major and two of the minor criteria
have to be fulfilled to diagnose PMF. PMF is characterized
by the presence of megakaryocyte proliferation and atyp-
ia, usually accompanied by either reticulin and/or collagen
fibrosis. In the absence of significant reticulin fibrosis, the
megakaryocyte changes must be accompanied by
increased bone marrow cellularity characterized by granu-
locytic proliferation and often decreased erythropoiesis
(i.e., prefibrotic cellular-phase disease). Two of the follow-
ing minor criteria have to be met in order to diagnose
PMF: leukoerythroblastosis, increase in serum lactate
dehydrogenase level, anemia, and palpable spleno -
megaly.1,2 Morphological criteria for ET require that bone
marrow histology exhibits proliferation mainly of the
megakaryocytic lineage with increased numbers of
enlarged, mature megakaryocytes. There should be no sig-
nificant increase or left-shift of neutrophilic granulopoiesis
or erythropoiesis.1,2 Although single center studies were
able to demonstrate a clinical significance of histology-
based discrimination of ET and PMF,8 the reproducibility
of the histological criteria has been questioned.4,6
In a recent very detailed study, 16 histopathological cri-
teria such as cellularity and megakaryocyte morphology
were analyzed for interobserver agreement and utility for
identifying ET and prefibrotic PMF.4 Substantial interob-
server variability was found for all criteria with the excep-
tion of reticulin grade.4
The European Bone Marrow Working Group initiated
the present study on the interobserver agreement in clas-
sification of MPN based on the  WHO criteria because: (i)
this classification is broadly applied; (ii) in contrast to the
newly proposed lymphoma classifications10,11 it has never
been evaluated for feasibility in a multicenter setting; (iii)
it introduces minor criteria which were not included in the
retrospective studies by Thiele and co-workers, who inau-
gurated the concept of PMF;9,12 and (iv) its practical utility
has been questioned.3,4,6
Five European centers participated in this study. In con-
trast to previous studies4,6 cases with overt fibrosis were
not included. Also, a complete classification, combining
histological and clinical data, was tested for reproducibili-
ty, rather than single histological parameters.
Furthermore, neither obvious opponents nor authors of
the MPN chapter of WHO classification were involved.
The review panel consisted of experienced hematopathol-
ogists, who apply the WHO criteria in their everyday
practice. No follow-up data with regard to progression to
myelofibrosis were available for the study cases. It was
beyond the scope of this study to evaluate the WHO cri-
teria for their ability to predict myelofibrosis. 
One hundred and two bone marrow biopsies from
patients with  non-reactive thrombocytoses were evaluat-
ed.  In the first round only age and platelet counts were
known to the panel members; in the second round clinical
data on leukoerythroblastosis, serum lactate dehydroge-
nase level, hemoglobin, and spleen size were added and a
revised diagnosis integrating clinical data was rendered. 
Design and Methods
Design of the study 
Six hematopathologists from five European countries, experi-
enced in bone marrow histology but not involved in the WHO
classification of MPN rendered independent diagnoses of ET, PMF,
or MPN unclassifiable (MPNuc) on a set of 102 bone marrow
trephines. Cases which were considered in consensus (4/6) as
inconclusive for MPN were excluded from the study (n=6). When
the diagnosis “inconclusive for MPN” was rendered by less than
four panel members this was counted as a diagnosis of unclassifi-
able MPN. In the first round the diagnosis was based on morphol-
ogy alone, and in the second round it included the knowledge of
further clinical and molecular data. From the six pathologists, five
contributed at least 20 cases. 
The inclusion criteria were as follows: (i) biopsy taken in the
period January 1st 2009- December 31st 2009; (ii) clinical suspicion
of MPN because of sustained thrombocytosis; (iii) histopathologi-
cal diagnosis of MPN (either ET or PMF); (iv) no fibrosis or fibrosis
grade 1; (v) biopsy size of ≥ 1cm. Consecutive cases were included
without further selection except abovementioned criteria (i) to (v). 
In the majority of cases information on spleen size, blood pic-
ture, JAK2 status, lactate dehydrogenase concentration, and blood
cell counts was available. In the other cases only incomplete data
were reported with one or more of the parameters lacking (n=31).
These cases were excluded from the second round of consensus
assessment. Due to anonymization of study patients the missing
clinical data could not be retrieved retrospectively. The clinical
data of the study population are summarized in Table 1.
From each block, five sets of stained slides were produced,
including slides stained with hematoxylin-eosin, Giemsa and
Gomori-silver stains and an unstained section for individual use.
Slides were sent to the participants together with information on
gender, age and platelet count. After morphological diagnoses had
been rendered, further clinical information on spleen size, blood
picture, JAK2 status, lactate dehydrogenase concentration, blood
cell counts and differential blood picture were distributed and the
participants then modified the diagnoses according to WHO
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Table 1. Clinical data of the study population.
Female 62%
Male 38%
Median age 65 years (22-91 years)
Anemia 14%
Leukocytosis (12¥109/L) 13%
Anemia and leukocytosis 2%
Increased spleen size 8%
Elevated lactate dehydrogenase 54%
Leukoerythroblastic blood picture 0%
JAK2mutation 50%
minor criteria for PMF. For the diagnosis of fibrotic as well as pre-
fibrotic PMF three out of three major criteria and at least two out
of four minor criteria (anemia, leukoerythroblastic blood picture,
increased serum lactate dehydrogenase, splenomegaly) have to be
fulfilled.1 A full set of data was available for 66 cases. A consensus
for a diagnosis was defined as four identical diagnoses (66.6%)
from the total of six that were given to each biopsy in both rounds.
Statistics
Interobserver agreement was assessed using the kappa statistic,
which takes into account the agreement expected solely on the
basis of chance and can be used if more than two categories are
classified. Total agreement is indicated by a value of 1.0, but agree-
ment by chance only results in a zero value.
Although there is no generally accepted value of kappa that
indicates sufficient (i.e. good) agreement in the literature, Landis
and Koch13 suggested the following guidelines: a kappa less than
0.4 represents poor-to-fair agreement, a kappa of 0.4 - 0.6 indicates
moderate agreement, from 0.6 - 0.8 indicates substantial agree-
ment and greater than 0.8 indicates almost perfect agreement. To
measure the grade of agreement, a weighted kappa-statistic was
calculated using the statistic software package SAS, version 8.0.
Below 0.1 was considered to indicate no agreement. 
The study was approved by the Ethics Committee of the
Medizinische Hochschule Hannover.
Results
The participants of the trial chose between four differ-
ential diagnoses: ET, PMF (prefibrotic or cellular phase),
MPNuc, inconclusive for MPN.
In the first round of assessment only 3% of cases
received four different diagnoses, indicating total disagree-
ment. Three different diagnoses were given in 18%. The
majority of cases (79%) were uniformly categorized or
had only two different diagnoses (Table 2). These num-
bers improved to 0% and 87%, respectively, after more
clinical data were incorporated to apply the WHO minor
criteria for PMF (Table 2). 
The most frequent diagnosis, agreed upon by at least
four participants was ET (37%), followed by PMF (24%).
When minor PMF criteria were considered, the frequency
of MPNuc rose to 23%, while PMF became less frequent
(7%).  
Complete consensus (100%) from all six hematopathol-
ogists concurring on a single morphological interpretation
was observed in only 10% of cases. This figure increased
to 17% when more detailed clinical data were considered.
Representative consensus cases of ET and PMF categories
are shown in Figure 1. At a consensus level of 83.3% (the
same diagnosis by five out of the six hematopathologists)
the figures were 35% in the first round and 32% in the
second round, respectively. When consensus was defined
by at least four out of the six hematopathologists coming
to identical conclusions, consensus was reached in 61%
and 64% of cases, respectively (Table 3).
In 12 cases, half of the panel members gave a morpho-
logical diagnosis of ET and half a diagnosis of PMF.
Representative examples are illustrated in Figure 1. These
cases were characterized by a slightly increased cellularity,
a range of megakaryocytic size but no dense cluster forma-
tion and a lower grade of megakaryocytic pleomorphism.
The number of ambiguous cases decreased from 12 to four
after clinical data were taken into consideration, but then
a comparably high number of divergent diagnoses was
seen between ET and MPNuc (14%). The percentage of
MPN cases considered by at least four participants as
unclassifiable rose from 2% to 23% after inclusion of
minor criteria for PMF, whereas the percentage of cases
with a firm PMF diagnosis dropped from 24% to 7%.
Thus, 71% of cases which would have been classified as
PMF exclusively on the ground of bone marrow histology
did not fulfill the complete WHO criteria.
When more clinical data became available, no cases
remained as inconclusive for MPN by consensus diagnosis
t. Buhr et al.
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Table 2. Number of diagnoses per case (ET, PMF, MPNuc or inconclu-
sive for MPN).
Number of diagnoses Without clinical With clinical 
data (%) data (%)
1 18 17
2 61 70
3 18 13
4 3 0
Figure 1. A case of typical ET (n. 77) for which six out of six pathol-
ogist concurred is depicted in (A) and (B). There is almost normal
cellularity with a proliferation of large megakaryocytes which do not
tend to form dense clusters and reveal staghorn like nuclei. In cases
uniformly diagnosed as PMF [n. 59; (C) and (D)], increased cellularity
with prominent proliferation of granulocytes was present, which was
not evident in typical ET cases. Megakaryocytes of varying size are
increased in number, have pleomorphic nuclei and form dense clus-
ters. In a number of cases bone marrow histology demonstrated
combined features which did not allow a clear-cut subtyping as in A-
D. Such a case (n. 61), which received a split classification (3:3) as
ET or PMF is shown in (E) and (F). The cellularity is only slightly
increased, there is a spectrum in megakaryocytic size but no cluster
formation and the pleomorphism of megakaryocytes is not pro-
nounced (A, C, E Giemsa x 100; B, D, F Giemsa x 400).  
A B
DC
E F
(four out of six participants).  Based on histology alone,
6% of cases fell into this category and were not consid-
ered further for the calculation of consensus. 
The concordance of diagnoses between pathologists
was measured by the kappa statistic. The agreement
between the diagnoses from each of the hematopatholo-
gists was determined, leading to 15 different kappa values.
Interobserver variability in the first round showed low to
moderate kappa values (0.28 to 0.57, average 0.41).
Moderate concordance rates were seen in six out of 15
possible paired combinations between observers, whose
agreement was compared (40% of all kappa values). Poor
concordance rates occurred in 60%. After consideration of
clinical data no concordance at all emerged for two out of
15 possible paired combinations between observers (13%
of all kappa values) (Table 4).
Discussion
Since Dameshek’s seminal description of the chronic
myeloproliferatve diseases as a group of interrelated dis-
eases14 there has been continuous controversy on how to
subtype the disorders which fall into this category. The
discovery of the JAK2 mutation15,16 confirmed that these
diseases not only share clinical and histopathological fea-
tures but are even more closely related because they have
a common molecular abnormality and hence most likely
also a shared pathogenesis. Consequently, these diseases
were grouped together as MPN by the WHO classifica-
tion.1,2 Despite considerable overlap not all MPN exhibit
the same risk of progression to either myelofibrosis or
acute leukemia. In particular Thiele et al. emphasized that
the risk of myelofibrosis is intrinsic to a special subtype of
MPN, which in its early stages is not fibrotic.9,12 The early
stage was named the cellular phase of idiopathic myelofi-
brosis and later the name was changed to prefibrotic
PMF.1,9 A number of histological features of the bone mar-
row, such as pleomorphism and clustering of megakary-
ocytes, help to distinguish early PMF from ET, which is
said not to exhibit a tendency to progress to overt fibrosis
or blast crisis.9 The WHO classification has adopted the
morphological criteria and combined them with clinical
criteria (minor criteria) to establish the diagnosis of PMF.1,2
Such a combination of criteria was not used in the purely
histological studies by Thiele et al.9,12 and to the best of our
knowledge has not been tested in clinical trials. This
approach has been challenged in particular by the groups
involved in the largest prospective therapy study on ET so
far.4,5
When the diagnoses rendered by six hematopatholo-
gists in cases which fall into the category of either ET or
PMF were compared, it became obvious that the interob-
server variability is high and only low to moderate kappa
values were achieved (Table 4). Only 13% of cases were
interpreted in complete consensus. At least four out of six
pathologists concurred in roughly two thirds of cases.
Whereas the subclassification is obviously a matter of sub-
jectivity, the diagnosis of MPN as such appears to be much
more reproducible. “Inconclusive for MPN” was diag-
nosed either in consensus (six cases before more detailed
clinical data were given, Table 3) or not at all (data not
shown). 
The current study shows that a considerable proportion
of cases which would have been categorized as cellular
idiopathic myelofibrosis or prefibrotic PMF on the
grounds of histological criteria alone became unclassifiable
Reproducibility of the diagnosis of prefibrotic myelofibrosis
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Table 3. Percentage of cases diagnosed in concordance.
Classification Agreement  ET PMF MPNuc Sum 
parameters of diagnosis (%) (%) (%) (%)
Round 1: Histology
6/6 5 5 0 10
5/6 15 10 0 25
4/6 17 9 2 28
consensus (%) 37 24 2 63
Round 2: Histology 
and clinical data
6/6 10 6 1 17
5/6 10 1 4 15
4/6 15 0 18 33
consensus (%) 35 7 23 65
Table 4. Concordance rates between pathologists (kappa values)*.
P 1 P 2 P 3 P 4 P 5 P  6
P1 Kappa 0.7814 0.3544 0.3278 0.2785 0.2783 0.5010
P< 0.0000 0.0000 0.0000 0.0024 0.0002 0.0000
P 2 Kappa 0.1059 0.7513 0.5739 0.3256 0.3882 0.4583
P< 0.1316 0.0000 0.0000 0.0002 0.0001 0.0000
P 3 Kappa 0.0358 0.2360 0.2505 0.3757 0.4930 0.5401
P< 0.4546 0.0327 0.0278 0.0000 0.0000 0.0000
P 4 Kappa 0.1473 -0.0411 0.0226 0.5564 0.4348 0.3759
P< 0.2226 0.5419 0.6175 0.0000 0.0000 0.0001
P 5 Kappa 0.2907 0.1390 0.1533 0.0766 0.7151 0.4013
P< 0.0026 0.2154 0.0819 0.4162 0.0000 0.0000
P 6 Kappa 0.5691 0.1318 0.4599 0.2699 0.1881 0.6087
P< 0.0000 0.0728 0.0373 0.0251 0.0601 0.0000 
*P= Pathologist 1-6, bold figures indicate kappa values after consideration of clinical data. Intraobserver concordance (diagonal numbers, marked grey)  was calculated by com-
parison of diagnoses in the first and in the second round.
when two minor criteria were also taken into considera-
tion. Many pathologists, including those who apply the
WHO criteria, may not be aware of the fact that a clear-
cut case of PMF on the basis of histology cannot be diag-
nosed histologically as such according to the WHO criteria
if the minor criteria are either not fulfilled or are not
known. Therefore, more than 50% of PMF cases diag-
nosed morphologically by at least four out of six panel
members, became MPNuc in this study when the WHO
criteria were applied. A similar figure was reported by
Campell et al.17
In pathology the typing and subtyping of most diseases
should have a high degree of interobserver reliability.
Classifications which can not guarantee this reliability
must be reconsidered. In contrast to typing and subtyping,
grading is known to be more prone to subjectivity with a
lower degree of reproducibility but it has the capacity to
roughly reflect differences in biology. Histomorphology
would, therefore, be expected to reflect biological differ-
ences between thrombocytic MPN more adequately if a
grading scheme were to be applied. 
A possible scheme is proposed which would be discrim-
inate between PV and ET within BCR-ABL-negative MPN.
Both diseases can progress to myelofibrosis. The likeli-
hood of ET doing this could be indicated by grading, par-
alleling the approach to PV. For example ET grade 1 could
stand for “true” ET without an increase in reticulin, and ET
grade 2 for cases with pleomorphic megakaryocytes
and/or granulocytic proliferation and/or grade 1 fibrosis
(corresponding to prefibrotic or cellular PMF). Grade 3 ET
would comprise those bone marrow samples which in
addition to the criteria for ET grade 2 exhibit overt fibro-
sis. The advantage of such a classification would be that it
fits better with the overlapping findings of JAK2 and MPL
mutations,18 and is in concordance with the approach to
PV, in which it is recognized that some cases of PMF may
follow undiagnosed PV. We suggest reserving the diagno-
sis of PMF for those cases with grade 3 fibrosis in the bone
marrow and which fulfill at least two of the four minor
criteria required for PMF by the WHO classification. In
this way, the emotively loaded term “myelofibrosis” will
be reserved for clinically relevant cases. 
Although there seems to be a limited reproducibility of
the histological category of PMF, differences in histology
are paralleled by constant variations in gene expression
between ET and PMF.18-21 The histological distinction,
which is widely accepted,8,9,22 does, therefore, appear to
have a biological basis and reflects differences in the
propensity to advance to myelofibrosis.  
This is confirmed by recent studies.23,24 In one of these
studies,23 carried out in two centers, a kappa value of 0.626
(substantial) was achieved when only morphology was
considered. This finding indicates that by training and con-
sensus panels the inter-observer agreement can potentially
be improved from moderate to substantial. In the current
study no consensus conference was organized. Consensus
conferences are not usually part of the every day practice
of well-trained hematopathologists whose work was
intended to be reflected in this study.  Furthermore, two of
the panelists were affiliated to the same institution.
Interestingly, the level of concordance between them did
not differ significantly from that found among the other
panelists. This finding suggests that consensus conferences
might lead to higher concordance rates which, however,
will most likely not persist under routine diagnostic cir-
cumstances. However, as close as an experiment on repro-
ducibility of diagnoses may come to reality it is not identi-
cal to the diagnostic situation in real life because of the lack
of therapeutic impact for patients and artificially high fre-
quency of similar cases. Consequently, the figures on con-
sensus cannot be extrapolated directly to clinical practice. 
In one of the studies reporting substantial concordance
rates between two centers on the basis of histology alone,
no patient in a series of 646 cases classified as having early
PMF had a leukoerythroblastic blood picture, more than
50% of patients had no anemia, roughly 50% of patients
did not have splenomegaly, and only a slight median
increase of lactate dehydrogenase was documented.23
From this compilation of data alone it can be concluded,
with high likelihood, that in this study minor WHO crite-
ria for PMF were not fulfilled in a considerable proportion
of patients with early PMF.23 Accordingly, the data suggest
that strict adherence to the WHO criteria in this study
would have led to a higher proportion of  MPNuc cases, as
seen in our study, a situation which is most unsatisfactory
for clinical decision-making.
The WHO classification scheme, which leads to a high
proportion of unclassifiable cases (23%) and causes dis-
crepant diagnoses in at least 36% of cases, may thus be
considered inadequate for routine clinical use or stratifica-
tion in prospective therapeutic trials. Until accurate,
prospective molecular markers for progression to myelofi-
brosis are available, pathologists and hematologists should
be aware of the potential prognostic value but also the
limited reproducibility of the currently applied histological
classification.
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